BioCorRx (BICX) Return on Sales (2011 - 2026)

BioCorRx has disclosed Return on Sales across 16 years of filings, most recently posting 0.04% for Q1 2026.

• Return on Sales for Q1 2026 came in at 0.04%, up 2.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.06% (up 29.0% YoY), and the FY2025 annual result was 0.04%, up 676.0% from the prior year.
• Return on Sales came in at 0.04% for Q1 2026 at BioCorRx, up from 0.09% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.02% in Q3 2025 to a low of 6.8% in Q4 2024.
• The 5-year median for Return on Sales is 0.46% (2022), against an average of 1.12%.
• Across the five-year window, Return on Sales tumbled 629 bps in 2024 and soared 671 bps in 2025, its largest moves.
• BioCorRx's Return on Sales stood at 0.14% in 2022, then tumbled by 266 bps to 0.51% in 2023, then sank by 1229 bps to 6.8% in 2024, then surged by 99 bps to 0.09% in 2025, then surged by 57 bps to 0.04% in 2026.
• The last three Return on Sales figures came in at 0.04% (Q1 2026), 0.09% (Q4 2025), and 0.02% (Q3 2025), per Business Quant data.